These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6979820)

  • 1. "Discoid" lupus erythematosus: dramatic clinical and immunological response to dialyzable leukocyte extract (transfer factor).
    Fudenberg HH; Strelkauskas AJ; Goust JM; Osborne D; Fort D; Vasily D
    Trans Assoc Am Physicians; 1981; 94():279-91. PubMed ID: 6979820
    [No Abstract]   [Full Text] [Related]  

  • 2. [Study of the circulating lymphocytes populations in systemic scleroderma, chronic discoid lupus erythematosus and dermatomyositis].
    Ramírez Bosca A; Valcuende Cavero F; Castells Rodellas A
    Med Cutan Ibero Lat Am; 1986; 14(5):306-10. PubMed ID: 3543549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The circulating lymphocyte profiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship.
    Wouters CH; Diegenant C; Ceuppens JL; Degreef H; Stevens EA
    Br J Dermatol; 2004 Apr; 150(4):693-700. PubMed ID: 15099365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical effectiveness of T-activin in the treatment of cutaneous forms of lupus erythematosus].
    Skripkin IuK; Biriukov AV; Stenina MA; Skripnik AIu; Korotkiĭ NG
    Vestn Dermatol Venerol; 1985 May; (5):8-11. PubMed ID: 3898631
    [No Abstract]   [Full Text] [Related]  

  • 5. [Diagnostic and prognostic significance of indicators of humoral and cellular immunity in patients with lupus erythematosus].
    Konstantinova NA; Koval'chuk LV; Cheredeev AN; Mattess Kh; Trofimova LIa
    Sov Med; 1983; (5):30-4. PubMed ID: 6612458
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cell immunity responses in patients with widespread neoplasias following administration of transfer factor (author's transl)].
    Simó-Camps E; Vich JM; García Calderón PA; Bofill D; Grau A; Anguiz A; Forcadell I
    Med Clin (Barc); 1980 May; 74(10):403-7. PubMed ID: 6968012
    [No Abstract]   [Full Text] [Related]  

  • 7. [Transfer factor (TF) - a modulator of immunological activity].
    Grubek-Jaworska H; Komorowska-Rycerz A
    Postepy Hig Med Dosw; 1981; 35(6):549-74. PubMed ID: 6752921
    [No Abstract]   [Full Text] [Related]  

  • 8. [Discoid lupus erythematosus and pregnancy (report of a case)].
    Reyes ME; Velázquez G
    Alergia; 1982 Jan; 29(1):19-23. PubMed ID: 7081633
    [No Abstract]   [Full Text] [Related]  

  • 9. Lymphocyte marker testing in relation to the clinical use of dialyzed leukocyte extract containing transfer factor (DLE-LTF).
    Peetoom F; Florey MJ
    Haematologia (Budap); 1980; 13(1-4):225-37. PubMed ID: 7250812
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical and immunological improvement in a patient with chronic mucocutaneous candidiasis treated with transfer factor.
    Businco L; Aiuti F; Franchi F; Frati C; Cavalieri R; Rezza E
    Allergol Immunopathol (Madr); 1976; 4(5):345-50. PubMed ID: 1087530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supressor activity of peripheral blood mononuclear cells in patients with chronic discoid lupus erythematosus.
    Hunyadi J; Dobozy A; Husz S; Kenderessy AS; Szegedi G; Simon N
    Arch Dermatol Res; 1979 Jul; 265(3):317-20. PubMed ID: 314274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfer factor: specific and nonspecific effects and chemical characteristics of dialyzable leukocyte lysates (DLL). Part II. Reconstituting effects dialyzable leukocyte lysates. (Second of three parts).
    Schindler TE; Baram P
    Allergol Immunopathol (Madr); 1980; 8(2):125-9. PubMed ID: 7457287
    [No Abstract]   [Full Text] [Related]  

  • 13. Guidelines for immunotherapy of antigen-specific defects with transfer factor.
    Wilson GB; Fudenberg HH; Keller RH
    J Clin Lab Immunol; 1984 Feb; 13(2):51-8. PubMed ID: 6202873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transfer factor therapy in osteogenic sarcoma.
    Levin AS; Byers VS; Fudenberg HH; Wybran J; Hackett AJ; Johnston JO
    Trans Assoc Am Physicians; 1974; 87():153-8. PubMed ID: 4549141
    [No Abstract]   [Full Text] [Related]  

  • 15. Changes in T cell and B cell composition in discoid lupus erythematosus skin at different stages.
    O'Brien JC; Hosler GA; Chong BF
    J Dermatol Sci; 2017 Mar; 85(3):247-249. PubMed ID: 27964878
    [No Abstract]   [Full Text] [Related]  

  • 16. [The treatment of isolated cellular immune defect with transfer factor (author's transl)].
    Göring HD; Fiehring C; Schröder I
    Dermatol Monatsschr; 1980 Feb; 166(2):81-7. PubMed ID: 6967428
    [No Abstract]   [Full Text] [Related]  

  • 17. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA.
    Wenzel J; Uerlich M; Wörrenkämper E; Freutel S; Bieber T; Tüting T
    Br J Dermatol; 2005 Nov; 153(5):1011-5. PubMed ID: 16225615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discoid lupus erythematosus and photosensitive eruptions.
    Perry HO
    Mod Treat; 1965 Sep; 2(5):908-15. PubMed ID: 5318849
    [No Abstract]   [Full Text] [Related]  

  • 19. [The activation of lupus in pregnancy and its successful immunological treatment].
    Tulokas S
    Duodecim; 1994; 110(23-24):2223-6. PubMed ID: 8654243
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases].
    Delaporte E; Catteau B; Sabbagh N; Gosselin P; Breuillard F; Doutre MS; Broly F; Piette F; Bergoend H
    Ann Dermatol Venereol; 1997; 124(2):151-6. PubMed ID: 9740825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.